Fevipiprant
Fevipiprant is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against prostaglandin D2 receptor 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
19 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asthma | D001249 | EFO_0000270 | J45 | — | 6 | 6 | — | 1 | 13 |
| Nasal polyps | D009298 | HP_0100582 | J33 | — | — | 1 | — | — | 1 |
| Polyps | D011127 | EFO_0000662 | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Eosinophilia | D004802 | HP_0001880 | D72.1 | — | 3 | — | — | — | 3 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | 1 | — | — | — | 1 |
| Lung diseases | D008171 | HP_0002088 | J98.4 | — | 1 | — | — | — | 1 |
| Obstructive lung diseases | D008173 | HP_0006536 | — | — | 1 | — | — | — | 1 |
| Allergic rhinitis | D065631 | — | J30.9 | — | 1 | — | — | — | 1 |
| Rhinitis | D012220 | EFO_0008521 | J31 | — | 1 | — | — | — | 1 |
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | — | 1 | — | — | — | 1 |
| Eczema | D004485 | HP_0000964 | L30.9 | — | 1 | — | — | — | 1 |
| Dermatitis | D003872 | HP_0011123 | L30.9 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
| Liver diseases | D008107 | HP_0002910 | K70-K77 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Fevipiprant |
| INN | fevipiprant |
| Description | Fevipiprant (INN; code name QAW039) is a drug of the piprant class that was being developed by Novartis. It is a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2 or CRTh2).
|
| Classification | Small molecule |
| Drug class | prostaglandin receptor antagonists, non prostinoid structure |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1c(CC(=O)O)c2cccnc2n1Cc1ccc(S(C)(=O)=O)cc1C(F)(F)F |
Identifiers
| PDB | — |
| CAS-ID | 872365-14-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3137332 |
| ChEBI ID | — |
| PubChem CID | 23582412 |
| DrugBank | — |
| UNII ID | 2PEX5N7DQ4 (ChemIDplus, GSRS) |
Target
Agency Approved
PTGDR2
PTGDR2
Organism
Homo sapiens
Gene name
PTGDR2
Gene synonyms
CRTH2, DL1R, GPR44
NCBI Gene ID
Protein name
prostaglandin D2 receptor 2
Protein synonyms
CD294, chemoattractant receptor homologous molecule expressed on T helper type 2 cells, Chemoattractant receptor-homologous molecule expressed on Th2 cells, G-protein coupled receptor 44, putative G-protein coupled receptor 44
Uniprot ID
Mouse ortholog
Ptgdr2 (14764)
prostaglandin D2 receptor 2 (Q9Z2J6)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 219 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use